Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00104923 · ClinicalTrials.gov registry record · Phase 1
Fenretinide in Treating Patients With Refractory or Relapsed Hematologic Cancer
A Phase 1 study of Lymphoma and Leukemia, sponsored by California Cancer Consortium.
- Completed
- Registry status
- Phase 1
- Development phase
- 29
- Enrollment target
- 4
- Study locations
NCT00104923: Completed Phase 1 study of Lymphoma and Leukemia, sponsored by California Cancer Consortium.
NCT00104923 is a Phase 1 study of Lymphoma and Leukemia that has completed, run by California Cancer Consortium. The registered enrollment target is 29 participants, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (94% lower). The trial reports 4 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00104923, a Phase 1 study of Lymphoma and Leukemia, has completed, sponsored by California Cancer Consortium.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 29 participants
- Enrollment target
- 4
- Study locations
Study Summary
RATIONALE: Drugs used in chemotherapy, such as fenretinide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving fenretinide in a different way may kill more cancer cells. PURPOSE: This phase I trial is studying the side effects and best dose of intravenous fenretinide in treating patients with refractory or relapsed hematologic cancer.
Conditions Studied
Interventions
- DRUG fenretinide
Study Locations (4)
Texas
- M. D. Anderson Cancer Center at University of Texas - Houston
- Joe Arrington Cancer Research and Treatment Center - Lubbock
California
- USC/Norris Comprehensive Cancer Center and Hospital - Los Angeles
Maryland
- Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2005-02 |
| Est. Completion | 2017-04 |
| Phase | Phase 1 |
What the finished NCT00104923 record still lists
NCT00104923 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 29 participants, a relatively small participant target, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (94% lower).
The record links to 4 conditions, with Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which fenretinide is the first listed.
NCT00104923 reports a single indexed study location in Texas, California, Maryland.
Frequently Asked Questions
What is clinical trial NCT00104923 about?
NCT00104923 is a clinical study titled "Fenretinide in Treating Patients With Refractory or Relapsed Hematologic Cancer". RATIONALE: Drugs used in chemotherapy, such as fenretinide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving fenretinide in a different way may kill more cancer cells. PURPOSE: This phase I trial is studying the side ef...
What is the current status of trial NCT00104923?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 29 participants. The study started on 2005-02. Estimated completion is 2017-04.
What conditions does trial NCT00104923 study?
This clinical trial studies the following conditions: Lymphoma, Leukemia, Multiple Myeloma and Plasma Cell Neoplasm, Chronic Myeloproliferative Disorders.
What interventions are being tested in trial NCT00104923?
The interventions under investigation include: fenretinide (DRUG).
Who is sponsoring clinical trial NCT00104923?
This trial is sponsored by California Cancer Consortium, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00104923 being conducted?
This trial has 4 study locations across California, Maryland, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00104923's enrollment target sits among peer trials
29 225th of 299 higher than 75 of 299 other Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase 1/2, Open-label Study of Valemetostat in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma
RECRUITING · Phase 1
-
TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas
RECRUITING · Phase 1
-
Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE
RECRUITING · Phase 1
-
CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies
RECRUITING · Phase 1
-
CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)
RECRUITING · Phase 1
-
A Study of TLN-254 in Participants With Relapsed or Refractory T-cell Lymphoma
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02429557 · 29 participants · Phase 1
Hemodynamic Mechanisms of Abdominal Compression in the Treatment of Orthostatic Hypotension in Autonomic Failure
- NCT02568878 · 29 participants · Phase 3
Creatine for Depressed Male and Female Methamphetamine Users
- NCT03014401 · 29 participants · NA
The Effect of Adipose-Derived Stem Cells for Knee Osteoarthritis
- NCT03128996 · 29 participants · Phase 1
Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia